Study of D-2570 in Subjects With Non-Segmental Vitiligo (D2570-206)
A Phase 2 Multicenter, Randomized, Parallel-group, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety and efficacy of D-2570 in subjects with non-segmental vitiligo. The study consists of three periods: a screening period (up to 4 weeks), a 24-week double-blind treatment period, and a 24-week extension treatment period, followed by a 4-week safety follow-up period.
During the screening period, written informed consent will be obtained from each subject, and eligibility will be assessed based on predefined inclusion and exclusion criteria. Subjects who meet all eligibility criteria will be stratified according to baseline vitiligo severity (T-VASI <15 or ≥15) and disease activity (active or stable), then randomized in a 1:1:1:1 ratio to one of four treatment groups: D-2570 Group A, D-2570 Group B, D-2570 Group C, or placebo.
During the 24-week double-blind treatment period, subjects will receive once-daily oral study medication. Subjects in Groups A and B will continue the same dose in the subsequent 24-week extension period. Subjects in Group C and the placebo group will be re-randomized in a 1:1 ratio to either Group A or Group B for the extension period, maintaining the blind.
All subjects will attend study visits at protocol-specified time points, including assessments of efficacy (including T-VASI), safety (including adverse events, clinical laboratory tests, vital signs, and physical examinations), and pharmacokinetic evaluations via blood sampling. The study will conclude with an end-of-study (EOS) visit at Week 52, 4 weeks after the last dose of study medication, to collect final safety data. All subjects, investigators, and study site personnel will remain blinded to treatment assignments throughout the study.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: shilin Sha
- Número de telefone: 15601826678
- E-mail: shilin.sha@inventisbio.com
Locais de estudo
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 201203
- Recrutamento
- Huashan Hospital, Fudan University
-
Contato:
- shilin Sha
- Número de telefone: 15601826678
- E-mail: shilin.sha@inventisbio.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Voluntarily signs informed consent and complies with study procedures.
- Age 18-65 years, male or female.
- Clinical diagnosis of non-segmental vitiligo at screening.
- F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo.
- Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.
Exclusion Criteria:
- - Segmental, mixed vitiligo or other concurrent pigmentary/active skin disorders interfering with study assessment.
- Over 33% facial or total vitiligo lesions with leukotrichia.
- Pregnant or breastfeeding females.
- Active, latent or inadequately treated tuberculosis infection.
- Positive HIV, active HBV/HCV infection, or untreated syphilis.
- Current or history of severe herpes infection.
- Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment.
- Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study.
- Uncontrolled thyroid disease, severe cardiovascular/cerebrovascular disease or other unstable severe systemic disorders.
- Severe psychiatric disease, suicidal ideation, or alcohol/drug abuse within 6 months.
- Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia).
- Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing.
- Clinically significant abnormal lab results: elevated liver/renal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts.
- History of severe drug hypersensitivity or drug-related toxicity.
- Any condition that may impair protocol compliance or study participation per investigator judgment.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: D-2570 Dose 1 (experimental arm 1)
Subjects in this arm will receive oral D-2570 Dose 1 once daily (QD) for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose of D-2570 Dose 1 in the subsequent 24-week extension period.
|
Oral D-2570 Dose 1 administered once daily for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose in the 24-week extension period
|
|
Experimental: D-2570 Dose 2 (experimental arm 2)
Subjects in this arm will receive oral D-2570 Dose 2 once daily (QD) for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose of D-2570 Dose 2 in the subsequent 24-week extension period
|
Oral D-2570 Dose 2 administered once daily for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose in the 24-week extension period.
|
|
Experimental: D-2570 Dose 3 (experimental arm 3)
Subjects in this arm will receive oral D-2570 Dose 3 once daily (QD) for 24 weeks during the double-blind treatment period.
After 24 weeks, subjects will be re-randomized to either D-2570 Dose 1 or Dose 2 once daily for the extension period.
|
Oral D-2570 Dose 3 administered once daily for 24 weeks during the double-blind treatment period.
Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
|
|
Comparador de Placebo: placebo
Subjects in this arm will receive matching placebo once daily (QD) for 24 weeks during the double-blind treatment period.
After 24 weeks, subjects will be re-randomized to either D-2570 Dose 1 or Dose 2 once daily for the extension period.
|
Oral placebo administered once daily for 24 weeks during the double-blind treatment period.
Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI)
Prazo: week24
|
Change rate of facial vitiligo area, measured by F-VASI score, relative to baseline
|
week24
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change and percentage change from baseline in F-VASI
Prazo: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Absolute change and percentage change in facial vitiligo area, measured by F-VASI score, relative to baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects achieving F-VASI50/75/90
Prazo: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in F-VASI score from baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Change and percentage change from baseline in T-VASI
Prazo: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Absolute change and percentage change in total vitiligo area, measured by T-VASI score, relative to baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects achieving T-VASI50/75/90
Prazo: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in T-VASI score from baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects with F-PhGVA score 0 or 1
Prazo: Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with F-PhGVA score of 0 (clear) or 1 (almost clear).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Proportion of subjects with T-PhGVA score 0 or 1
Prazo: Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with T-PhGVA score of 0 (clear) or 1 (almost clear).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Proportion of subjects with VNS score 4 or 5
Prazo: Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with VNS score of 4 (hardly noticeable) or 5 (not noticeable).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Change from baseline in DLQI score
Prazo: Weeks 8, 16, 24, 32, 40, and 48
|
Change in Dermatology Quality of Life Index (DLQI) score relative to baseline.
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Change from baseline in VitiQoL score
Prazo: Weeks 8, 16, 24, 32, 40, and 48
|
Change in Vitiligo-Specific Quality of Life (VitiQoL) score relative to baseline.
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Plasma concentrations of D-2570
Prazo: Through study completion (approximately Week 48)
|
Through study completion (approximately Week 48)
|
|
|
Safety of D-2570（AEs）
Prazo: Through study completion (approximately Week 48)
|
Through study completion (approximately Week 48)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- D2570-206
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .